Despite a lengthy review process by the U.S. FDA, several Gujarat-based pharmaceutical firms are preparing to debut a range of new drugs in the U.S. market in the current fiscal year. Alembic Pharmaceuticals says it has submitted 57 abbreviated new-drug applications and already launched 15 new products. Intas Pharma anticipates introducing about 10 to 15 new drug products in the U.S. in the areas of chronic diseases and oncology.

Related Summaries